NUTRESTORE (l-glutamine) by Emmaus Life Sciences is l-glutamine in treating sickle cell disease (scd) is not fully understood. First approved in 2004.
Drug data last refreshed 10h ago · AI intelligence enriched 3w ago
NUTRESTORE is an oral L-glutamine powder formulation approved for sickle cell disease that works by improving NAD redox potential in sickle red blood cells, thereby reducing oxidative stress and potentially decreasing hemolysis and vaso-occlusive events. The mechanism leverages glutamine's role in increasing reduced glutathione availability to protect sickle cells from oxidative damage.
As a niche SCD therapy approaching loss of exclusivity with moderate competitive pressure (30), the brand team is likely small and focused on defending market position against new entrants rather than growth expansion.
L-glutamine in treating sickle cell disease (SCD) is not fully understood. Oxidative stress phenomena are involved in the pathophysiology of SCD. Sickle red blood cells (RBCs) are more susceptible to oxidative damage than normal RBCs, which may contribute to the chronic hemolysis and vaso-occlusive…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Clinical Study of Alanyl-Glutamine for Reduction of Post-Myomectomy Adhesions
Clinical Trial of Alanyl-Glutamine or Glycine in Children With Persistent Diarrhea or Malnutrition
L-Glutamine Therapy for Sickle Cell Anemia
Worked on NUTRESTORE at Emmaus Life Sciences? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Joining the NUTRESTORE team at this lifecycle stage means working in a defensive, mature-asset environment focused on market protection and patient access rather than growth or launch excitement. Career development opportunities are concentrated in commercial strategy, reimbursement defense, and physician relationship management in the rare disease hematology space.